EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder. It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.